(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority ORDER New Delhi, the 6 th January, 208 S. O. 270(E) In exercise of the powers conferred by paragraphs 5, and 5 of the Drugs (Prices Control) Order, 203, read with S.O. 394(E) dated the 30 th May, 203 and S. O. 70(E) dated 0 th March, 206 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; Sl. No. Name of the Scheduled Formulation / Brand Name Table Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) () (2) (3) (4) (5) (6). Glimepiride + 4.89 2. Glimepiride + 3. Cilnidipine + Metoprolol Tablet 4. Escitalopram + Clonazepam Tablet (CENSPRAM MINI) 5. Ceftriaxone sodium & Tazobactam Sodium Injection Each uncouted Bi- Layered tablet Glimepiride IP mg, Metformin HCL IP 850mg (As sustained release form) Each uncouted Bi- Layered tablet Glimepiride IP 2mg, Metformin HCL IP 850mg (As sustained release form) Each film couted Bi- Layered tablet Cilnidipine 0mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (ER) Each film coated tablet Escitalopram Oxalate IP eq. to Esccitalopram 5mg Clonazepam IP 0.5mg Each combipack Ceftriaxone sodium (sterile) eq. to anhydrous Ceftriaxone 500mg Tazobactam Sodium (sterile) eq. to anhydrous Tazobactam 62.5mg, And Tablet M/s Windlas Biotech Ltd. / M/s Intas Pvt. Ltd. Tablet M/s Windlas Biotech Ltd. / M/s Intas Pvt. Ltd. Tablet M/s Safetab Life Science and Marketer /M/s Intas Pvt. Ltd. Tablet M/s Accent Pharma / M/s USV Each pack M/s Mankind Pharma Ltd. 7.23 6.98 5.73 76.69
6. Olmesartan + Amlodipine Tablet (Tripinom 40) 7. Rosuvastatin + Aspirin (Rozucorn Asp 20 Forte) 8. Rosuvastatin + (Unistar Gold 0/75) 9. Rosuvastatin + (Zyrova Gold 0) 0. Rosuvastatin +. Rosuvastatin + 2. Rosuvastatin + One FFS Ampoule containing Sterile water for injection 5ml Each uncoated tablet Olmesartan Medoxomil 40mg, Amlodipine Besylate eq. to Amlodipine 5mg, Hydrochlorothizide 2.5mg Each hard gelatine capsule Rosuvastatin Calcium eq. to Rosuvastatin 20mg (As film Aspirin IP 50mg (as enteric Rosuvastatin 0mg (As Pellets), 75mg (As Pellets) Rosuvastatin 0mg (As 75mg (As two film Rosuvastatin 0mg (As 75mg (As two film Rosuvastatin 0mg (As Pellets), 75mg (As Pellets) Rosuvastatin 0mg (As Pellets), Per Tablet M/s Accent Pharma / M/s Lupin Ltd. M/s Torrent Ltd. Pharma / M/s Unichem Laboratories Ltd. Pharma M/s Cadila Healthcare Ltd. Pharma / M/s Zuventus Healthcare Ltd /M/s Zydus Healthcare Ltd / M/s Mankind Pharma 2.29 8.78.70.70.70.70.70
3. Rosuvastatin + 4. Rosuvastatin + 5. Rosuvastatin + 6. Rosuvastatin + (Unistar Gold 20/75) 7. Rosuvastatin + (Zyrova Gold 20) 8. Rosuvastatin + 75mg (As Pellets) Rosuvastatin 0mg, Aspirin IP 75mg, 75mg Rosuvastatin 0mg (As film, Aspirin IP 75mg (As Gastro resistant tablet), 75mg (As film Rosuvastatin 0mg, Aspirin IP 75mg, 75mg 75mg (As Pellets) Rosuvastatin 20mg (As 75mg (As two film Rosuvastatin 20mg (As Ltd / M/s Cadila M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Jubilant Life Sciences Ltd / M/s Eris Lifesciences Ltd. Pharma / M/s Unichem Laboratories Ltd. Pharma /M/s Cadila Healthcare Ltd. Pharma /M/s Zuventus Healthcare.70.70.70 8.00 8.00 8.00
75mg (As two film 9. Rosuvastatin + 8.00 75mg (As Pellets) Ltd /M/s Zydus Healthcare 20. Rosuvastatin + 8.00 75mg (As Pellets) Ltd/ M/s Mankind Pharma 2. Rosuvastatin + 8.00 75mg (As Pellets) Ltd /M/s Lifestar Pharma 22. Rosuvastatin + M/s Pure and Cure 8.00 (Jubira Gold 20) Rosuvastatin 20mg (As film, Aspirin IP 75mg (As Gastro resistant tablet), 75mg (As film Healthcare Pvt. Ltd. /M/s Jubilant Life Sciences 23. Rosuvastatin + 8.00 Rosuvastatin 20mg, Aspirin IP 75mg, 75mg Ltd /M/s Eris Lifesciences Ltd. 24. Rosuvastatin + M/s Safetab 8.00 Rosuvastatin 20mg (As film,, 75mg (As film Lifescience M/s Lupin 25. Voglibose + Each uncoated bilayer tablets Tablet M/s ACME Generics 6.786
Glimeperide + (Glimy MVI) 26. Voglibose + Glimeperide + (Glimy MV2) 27. Cefixime + Ofloxacin Tablet (Stancef-O Plus) 28. Trypsin + Bromelain + Rutoside + Diclofenac Tablet (Volitra Enzo) 29. Gliclazide + (GLZ MEX) 30. Rosuvastatin + (Turbovas C) Voglibose IP 0.2mg, Glimeperide IP mg & Metformin Hydrochloride IP 500mg (SR) Each uncoated bilayer tablet Voglibose IP 0.2mg, Glimeperide IP 2mg & Metformin Hydrochloride IP 500mg (SR) Each film coated tablet Cefixime Trihydrate eq. to Cefixime Anhydrous IP 200mg, Ofloxacin IP 200mg Each enteric coated tablet Trypsin BP 48mg, Bromelain 90mg, Rutoside Trihydrate BP 00mg Diclofenac Sodium IP 50mg Each film coated tablet Gliclazide IP 60mg (In modified release form), Metformin HCL 500mg (extended release form) Each hard gelatine capsule Rosuvastatin Calcium IP eq. to Rosuvastatin 0mg (as film coated tablet), Bisulphate IP eq. to 75mg (as 2 film / M/s Dr. Reddy's Laboratories Tablet M/s ACME Generics / M/s Dr. Reddy's Laboratories Tablet M/s Theon a/ M/s Sun Pharmaceutical Industrial Tablet / M/s Sun Industries Tablet M/s Mascot Health Seris Pvt. Ltd. / M/s Alembic M/s Micro Labs 8.57 9.46 3.85 7.65 2.95 Note: (a) The manufacturer of above mentioned formulations i.e. new drug under paragraph 2(u) of the DPCO, 203 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph of the DPCO, 203. The manufacturer shall issue a price list in Form V from date of Notification as per paragraph 24 of the DPCO, 203 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 203, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for
price fixation / revision as stipulated under DPCO, 203 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 203 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 203 at least six months prior to the intended date of discontinuation. (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 203 read with the Essential Commodities Act, 955. (h) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. PN/84/52/207/F F. No. 8(52)/207/D.P./NPPA-Div.-II (BALJIT SINGH) Assistant Director